JPWO2021075536A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021075536A5
JPWO2021075536A5 JP2021552459A JP2021552459A JPWO2021075536A5 JP WO2021075536 A5 JPWO2021075536 A5 JP WO2021075536A5 JP 2021552459 A JP2021552459 A JP 2021552459A JP 2021552459 A JP2021552459 A JP 2021552459A JP WO2021075536 A5 JPWO2021075536 A5 JP WO2021075536A5
Authority
JP
Japan
Prior art keywords
diabetes
composition
abnormal
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552459A
Other languages
English (en)
Japanese (ja)
Other versions
JP7784120B2 (ja
JPWO2021075536A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/039045 external-priority patent/WO2021075536A1/ja
Publication of JPWO2021075536A1 publication Critical patent/JPWO2021075536A1/ja
Publication of JPWO2021075536A5 publication Critical patent/JPWO2021075536A5/ja
Priority to JP2023117134A priority Critical patent/JP2023139101A/ja
Application granted granted Critical
Publication of JP7784120B2 publication Critical patent/JP7784120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552459A 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療 Active JP7784120B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023117134A JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019191369 2019-10-18
JP2019191369 2019-10-18
PCT/JP2020/039045 WO2021075536A1 (ja) 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117134A Division JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Publications (3)

Publication Number Publication Date
JPWO2021075536A1 JPWO2021075536A1 (https=) 2021-04-22
JPWO2021075536A5 true JPWO2021075536A5 (https=) 2022-08-09
JP7784120B2 JP7784120B2 (ja) 2025-12-11

Family

ID=75538075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552459A Active JP7784120B2 (ja) 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療
JP2023117134A Withdrawn JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023117134A Withdrawn JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Country Status (7)

Country Link
US (1) US20220403032A1 (https=)
EP (1) EP4035680A4 (https=)
JP (2) JP7784120B2 (https=)
KR (1) KR20220103718A (https=)
CN (1) CN114828890A (https=)
AU (1) AU2020367414A1 (https=)
WO (1) WO2021075536A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152099A (ko) * 2021-02-26 2023-11-02 가부시키가이샤 바이오지프코드 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제
IL312393A (en) * 2021-10-29 2024-06-01 Biozipcode Inc A method or factor with an HDAC regulator, for the treatment of diabetes and complications
CN115671112A (zh) * 2022-07-29 2023-02-03 中南民族大学 阿法替尼在防治二型糖尿病中的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
AU2007271163B2 (en) * 2006-07-06 2012-08-23 Merck Serono Sa CSF3R polypeptides and uses thereof
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
EP2182976A4 (en) 2007-08-31 2012-01-25 Massachusetts Inst Technology TREATMENT OF AUTOIMMUNE DISEASES
JP2015024960A (ja) * 2011-11-17 2015-02-05 公益財団法人東京都医学総合研究所 Ｃｘｃｒ４活性阻害ペプチド及びその用途
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016201214A1 (en) * 2015-06-12 2016-12-15 Stc. Unm Human glut5 specific inhibitors and methods of treatment
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP7087631B2 (ja) 2018-04-25 2022-06-21 住友電気工業株式会社 光接続部品及び光接続部品の製造方法

Similar Documents

Publication Publication Date Title
JPWO2021075536A5 (https=)
AU2018280264B2 (en) Compositions and methods for preventing or treating muscle conditions
Martínez-Iglesias et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
AU2003219803B8 (en) Method of treating TRX mediated diseases
Zhang et al. Sodium butyrate prevents lethality of severe sepsis in rats
J Shuttleworth et al. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases
WO2010123507A1 (en) Treatment of non-localized inflammation with pan-hdac inhibitors
US8883148B2 (en) Prevention of joint destruction
WO2011017448A1 (en) Use of histone deacetylase inhibitors for treatment of autoimmune diseases
JPWO2022181797A5 (https=)
Hussain et al. Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies
Ruzzon et al. Environment and arthritis
Kim et al. A novel dithiol amide CB3 attenuates allergic airway disease through negative regulation of p38 mitogen-activated protein kinase
Yamanaka New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review
JP2008520682A (ja) ヒストンデアセチラーゼ阻害剤およびその使用方法
El Barnawi et al. Serum cytokine levels in psoriasis vulgaris
JP2014520889A (ja) 非抗凝固性硫酸化多糖の経口製剤を改善するための添加剤としての吸収促進剤
Yang et al. The emerging spectrum of early life exposure-related inflammation and epigenetic therapy
EP1719543A1 (en) Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
Almansa et al. A comprehensive review of eosinophilic esophagitis in adults
M Halfaya et al. Effect of Platelet-rich Plasma on MMP-13, ARE and TGF β1 in MIA-Induced Osteoarthritis in Rats
JP2013227256A (ja) 血管内皮機能改善剤
Yang et al. Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis.
Li et al. n-3 polyunsaturated fatty acids inhibit the IL-1β/SP positive feedback loop in intervertebral disc endplate and low back pain-related behaviors in mice
RU2479312C1 (ru) Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии